Literature DB >> 29514783

High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.

Anne M R Schrader1, Patty M Jansen1, Rein Willemze2, Maarten H Vermeer2, Anne-Marie Cleton-Jansen1, Sebastiaan F Somers3, Hendrik Veelken3, Ronald van Eijk1, Willem Kraan4, Marie José Kersten5, Michiel van den Brand4, Wendy B C Stevens6, Daphne de Jong7, Myrurgia Abdul Hamid8, Bea C Tanis9, Eduardus F M Posthuma10, Marcel Nijland11, Arjan Diepstra12, Steven T Pals4, Arjen H G Cleven1, Joost S P Vermaat3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29514783     DOI： 10.1182/blood-2017-12-822817

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  17 in total

Review 1.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

2.  Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.

Authors:  Kazuyuki Shimada; Kenichi Yoshida; Yasuhiro Suzuki; Chisako Iriyama; Yoshikage Inoue; Masashi Sanada; Keisuke Kataoka; Masaaki Yuge; Yusuke Takagi; Shigeru Kusumoto; Yasufumi Masaki; Takahiko Ito; Yuichiro Inagaki; Akinao Okamoto; Yachiyo Kuwatsuka; Masahiro Nakatochi; Satoko Shimada; Hiroaki Miyoshi; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Satoru Miyano; Yusuke Shiozawa; Yasuhito Nannya; Asako Okabe; Kei Kohno; Yoshiko Atsuta; Koichi Ohshima; Shigeo Nakamura; Seishi Ogawa; Akihiro Tomita; Hitoshi Kiyoi
Journal:  Blood       Date:  2021-03-18       Impact factor: 22.113

Review 3.  Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.

Authors:  Thomas A Ollila; Adam J Olszewski
Journal:  Curr Treat Options Oncol       Date:  2018-06-21

4.  Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.

Authors:  Ruben A L de Groen; Ronald van Eijk; Stefan Böhringer; Tom van Wezel; Richard Raghoo; Dina Ruano; Patty M Jansen; Inge Briaire-de Bruijn; Fleur A de Groot; Karin Kleiverda; Liane Te Boome; Valeska Terpstra; Henriette Levenga; Alina Nicolae; Eduardus F M Posthuma; Isabelle Focke-Snieders; Lizan Hardi; Wietske C E den Hartog; Lara H Bohmer; Pancras C W Hogendoorn; Anke van den Berg; Arjan Diepstra; Marcel Nijland; Pieternella J Lugtenburg; Marie José Kersten; Steven T Pals; Hendrik Veelken; Judith V M G Bovée; Arjen H G Cleven; Joost S P Vermaat
Journal:  Blood Adv       Date:  2021-10-12

5.  PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy.

Authors:  Yuka Suzuki; Kei Kohno; Kosei Matsue; Ayako Sakakibara; Eri Ishikawa; Satoko Shimada; Kazuyuki Shimada; Seiyo Mabuchi; Taishi Takahara; Seiichi Kato; Shigeo Nakamura; Akira Satou
Journal:  Cancer Med       Date:  2020-05-05       Impact factor: 4.452

6.  Pathological mutations differentially affect the self-assembly and polymerisation of the innate immune system signalling adaptor molecule MyD88.

Authors:  Ailís O'Carroll; Brieuc Chauvin; James W P Brown; Ava Meagher; Joanne Coyle; Jurgen Schill; Akshay Bhumkhar; Dominic J B Hunter; Thomas Ve; Bostjan Kobe; Emma Sierecki; Yann Gambin
Journal:  BMC Biol       Date:  2018-12-24       Impact factor: 7.431

7.  MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.

Authors:  Joost S Vermaat; Sebastiaan F Somers; Liesbeth C de Wreede; Willem Kraan; Ruben A L de Groen; Anne M R Schrader; Emile D Kerver; Cornelis G Scheepstra; Henriëtte Berenschot; Wendy Deenik; Jurgen Wegman; Rianne Broers; Jan-Paul D de Boer; Marcel Nijland; Tom van Wezel; Hendrik Veelken; Marcel Spaargaren; Arjen H Cleven; Marie José Kersten; Steven T Pals
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

Review 8.  MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications.

Authors:  Ruben A L de Groen; Anne M R Schrader; Marie José Kersten; Steven T Pals; Joost S P Vermaat
Journal:  Haematologica       Date:  2019-11-07       Impact factor: 9.941

9.  Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system.

Authors:  Sang Eun Yoon; Won Seog Kim; Seok Jin Kim
Journal:  Korean J Intern Med       Date:  2019-11-25       Impact factor: 2.884

10.  Towards genomic-based prognostication and precision therapy for diffuse large B-cell lymphoma.

Authors:  Marthe Minderman; Steven T Pals
Journal:  Haematologica       Date:  2020-09-01       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.